PAMS
SGMO

Pictet Asset Management (Switzerland)’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,462
Closed -$41.3K – 2011
2023
Q1 		$41.3K Hold
23,462
– – ﹤0.01% 1954
2022
Q4 		$74K Buy
+23,462
New +$91.1K ﹤0.01% 1922

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s SGMO Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 23,462 shares — an estimated $41.3K sold.

Pictet Asset Management (Switzerland) first reported a position in SGMO in Q4 2022 and held it in 2 quarters. The position peaked at $74K in Q4 2022. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

  • Pictet Asset Management (Switzerland) reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
  • Pictet Asset Management (Switzerland) sold 23,462 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $41.3K.
  • Pictet Asset Management (Switzerland) first reported a position in SANGAMO THERAPEUTICS INC in Q4 2022 and held it in 2 quarters.
  • Pictet Asset Management (Switzerland)'s SANGAMO THERAPEUTICS INC position peaked at $74K in Q4 2022.
  • 152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.